Table 1 Antibody responses to primary HSV-1 infection.

From: Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity

Assay

Median

Range

n

HSV-1 IgG

   

 Female

30,000

1000–270,000

63

 Male

90,000

10,000–270,000

15

Neutralizing Titer

   

 Female

200

25–400

18

 Male

200

50–400

10

FcγRIV activation

   

 Female

1.345

0.01–6.83

63

 Male

0.735

0.05–5.39

15

gB-1 IgG (Female)

270,000

10,000–270,000

16

gD-1 IgG (Female)

27, 000

30,000–270,000

32

  1. HSV-1, gB-1, and gD-1 IgG titers were determined by ELISA and are reported as endpoint dilutions of immune serum (cutoff optical density units at 450 nm of 0.2). Neutralizing titers are defined as the highest dilution of immune serum that inhibited 50% of HSV-1 viral plaque formation. The FcγRIV activation is reported as fold-induction after subtracting background.